Introduction
Antimicrobial stewardship programmes (ASPs) have consistently demonstrated the ability to significantly reduce antimicrobial use and cost. 1 Although drug-based stewardship is the cornerstone of successful ASPs, programmes are also well positioned to improve patient outcomes through disease-based antimicrobial stewardship for targeted infectious diseases by promoting compliance with performance and process measures. According to national guidelines, the primary goal of ASPs is to optimize patient outcomes, which aligns with the focus of healthcare shifting towards increased emphasis on quality, safety and patient outcome metrics linked to specific disease states. [2] [3] [4] The recently published IDSA/Society for Healthcare Epidemiology of America (SHEA) guideline on implementation of ASPs recommends interventions to improve clinical outcomes targeted at patients with specific infectious diseases. 3 Additionally, the CDC's Core Elements of ASPs highlights the need for diagnosis-and infection-specific interventions. 5 This expanded focus of ASPs may be more clinically and financially meaningful to institutions as implementing initiatives with the potential to reduce length of hospitalization and readmissions for specific diseases often results in more sustained cost savings than activities focused solely on antimicrobial utilization. 4 Disease-based stewardship initiatives have been implemented through a diverse array of strategies, which may be broadly classified as active or passive ( Table 1 ). The primary active strategy recommended in IDSA/SHEA stewardship guidelines is prospective audit with intervention and feedback. 2, 3 This typically requires the identification of patients based on a prescribed antimicrobial or disease state and subsequently providing patient-specific feedback to the treating provider on the current management plan. Active intervention is often time and resource consuming and requires clinical expertise, which may be a barrier for institutions initiating new ASPs with limited resources. Passive initiatives include those impacting antimicrobial utilization or disease state management without patient-specific intervention, such as providing education, developing an institutional guideline or implementing an algorithm in the electronic medical record. While passive strategies can be applied broadly, it is unclear whether active intervention is required to improve the management of all infectious diseases. The following review will describe published active and passive disease-based stewardship interventions and their impact on antimicrobial use and associated patient outcomes for patients with pneumonia, acute bacterial skin and skin structure infections (ABSSSIs), bloodstream infections (BSIs), urinary tract infections (UTIs), asymptomatic bacteriuria (ASB), Clostridium difficile infection (CDI) and intra-abdominal infections (IAIs).
Methods
A comprehensive literature search for studies assessing disease-based stewardship initiatives was conducted using the PubMed database. Search terms included, but were not limited to, combinations including 'stewardship', 'guideline', 'clinical pathway', 'antibiotic management', 'bloodstream', V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
'bacteremia', 'candidemia', 'fungemia', 'urinary tract infection', 'asymptomatic bacteriuria', 'pneumonia', 'respiratory tract infection', 'intra-abdominal', 'skin soft tissue infection', 'abscess', 'cellulitis', 'diabetic foot infection', 'Clostridium difficile', 'rapid diagnostic test' and 'infection'. In addition, the references of these studies were reviewed to identify additional publications that were not identified via the search terminology. Studies written in English published up to April 2017 were reviewed. To be included, studies must have clearly described an intervention and evaluated the impact of disease-based stewardship measures on antimicrobial utilization or patient outcomes.
BSIs
BSIs are common healthcare-associated infections and are associated with high morbidity and mortality. [6] [7] [8] Many institutions have implemented guidelines and pathways to provide direction for empirical and definitive antimicrobial selection for BSIs. Institutional guideline development and clinician education have resulted in increased guideline compliance in few retrospective studies. [9] [10] [11] [12] However, exclusively passive interventions have demonstrated limited improvements with regard to patient outcomes, such as mortality and length of stay (LOS), thus propagating a shift towards active interventional methods (Tables S1-S4, available as Supplementary data at JAC Online).
Prompt initiation of effective antimicrobial therapy is associated with improved clinical outcomes and is a common focus of ASPs targeting BSIs. 13 Most microbiology laboratories directly notify providers of Gram stain results from positive blood cultures, yet subsequent notification of organism identification and antimicrobial susceptibilities is often lacking and may result in delays in effective or optimal antimicrobial therapy. In response, ASPs have implemented prospective monitoring of patients with bacteraemia in order to promptly disseminate microbiological information and treatment recommendations. [14] [15] [16] [17] These active interventions have improved time to effective therapy, even in the absence of rapid diagnostic technologies (RDTs), and some have also observed improvements in clinical outcomes. 14, 15, 17, 18 Without the concomitant use of RDT, Pogue et al.
14 focused on Gramnegative bacteraemia and demonstrated improvements in LOS (OR 0.76; 95% CI 0.66-0.86) and infection-related mortality (OR 0.24; 95% CI 0.08-0.76) in the subset of patients who were not initially on appropriate antimicrobial therapy. Similarly, without RDT, Bias et al. 18 observed a lower rate of infection-related mortality (25.8% versus 11.3%, P " 0.047) with ASP notification of microbiology results and initiation of antimicrobial therapy. Through primarily pre/post quasi-experimental studies, many ASPs have demonstrated improvements in clinical outcomes by combining RDT with real-time alerting and intervention. 14, [19] [20] [21] [22] [23] [24] [25] [26] [27] Use of RDTs such as MALDI-TOF MS, PCR and fluorescence in situ hybridization with peptide nucleic acid probes facilitates a reduction in time to organism identification by 1-3 days. 20, 25, 27, 28 Coupling RDT with ASP alerting and intervention has consistently resulted in reductions in time to effective and optimal therapy, [20] [21] [22] 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] with some studies additionally demonstrating improvements in LOS 14, [19] [20] [21] [22] [23] 34, 35 and mortality. 21, [24] [25] [26] [27] 38 Of note, the hours of realtime operations varied between studies and interventions were primarily provided by pharmacists or physicians with infectious diseases expertise. Comprehensive reviews evaluating the use of RDTs have recently been published and highlight the important role of active and timely ASP intervention to order to achieve improvements in patient outcomes. 36, [39] [40] [41] [42] [43] There are only two randomized controlled trials evaluating the impact of ASP intervention in the management of BSIs. 44, 45 Banerjee et al. 44 randomized 617 patients with bacteraemia into three groups: (i) control group; (ii) rapid multiplex PCR (rmPCR) organism identification, including mecA, vanA/B and bla KPC gene identification, with templated comments; and (iii) rmPCR with templated comments and real-time alerting and intervention by an ASP. All groups utilized MALDI-TOF MS for organism identification and rapid testing for methicillin resistance on Staphylococcus aureus colonies with the Alere PBP2a test. Templated comments, reported in the electronic medical record, were designed to provide clinicians with organism-specific treatment recommendations. For example, for MSSA, the comment stated: 'Preferred therapy is an anti-staphylococcal b-lactam antibiotic, unless clinically contraindicated.' Significant reductions in piperacillin/tazobactam and increases in antistaphylococcal penicillin and cefazolin durations of therapy were observed in both rmPCR arms compared with the control. However, only the group receiving active ASP intervention observed significant reductions in unnecessary vancomycin duration of therapy, time to first appropriate de-escalation and time to first appropriate escalation. There were no significant differences in clinical or microbiological outcomes between any of the groups. 44 Cairns et al. 45 performed a multicentre study that randomized 160 bacteraemic patients to receive either (i) the 45 In summary, the ability of ASPs to optimize antimicrobial therapy for BSIs has been supported by randomized controlled trials, yet improvements in clinical outcomes observed in quasi-experimental studies have yet to be confirmed in studies with stronger study design.
S. aureus and Candida spp. represent a large portion of healthcare-associated and hospital-acquired BSIs and are associated with high mortality, prolonged LOS and increased cost compared with other bacterial BSIs.
46,47 S. aureus bacteraemia (SAB) is a complex disease that requires multifaceted intervention to ensure proper management. Infectious diseases consultation results in improvements in outcomes associated with SAB, 8, [48] [49] [50] [51] [52] [53] which is likely due to increased adherence to key process measures. Consequently, a bundle approach may be a useful strategy in improving the management of SAB, wherein a standardized set of interventions are developed into a management protocol. Bundle implementation alone, similar to a guideline, is a passive ASP strategy; however, an active component may be incorporated through reinforcement and utilization of the bundle by ASPs or infectious diseases consultation services. To date, five studies have utilized active bundle approaches and only one of these studies utilized an ASP, rather than infectious diseases consultation alone, to reinforce the bundled interventions. 54 Similarities among the bundles included obtaining repeat blood cultures, initiating b-lactam therapy for MSSA infection, obtaining echocardiography for qualifying patients, [50] [51] [52] 54, 55 removing foci of infection and recommending appropriate duration of therapy. 50, 51, 54, 55 These active initiatives demonstrated improvements in the management of SAB beyond antibiotic use; significant increases in obtaining repeat blood cultures, 52, 54, 55 removal of foci of infection, 50, 54, 55 and echocardiography 50, 52, 55 were observed. Despite these improvements, effects on clinical outcomes have varied, likely a result of differing bundle elements and patient populations (Table S1 ). Furthermore, one study observed an improvement in bundle adherence (56% versus 84%, P , 0.001) and a reduction in readmission with recurrent SAB (11% versus 1%, P " 0.008) with ASP reinforcement of bundle elements, even though rates of infectious diseases consultation remained similar between comparator groups (85% versus 89%, P " 0.649). 54 Consequently, a focus on achieving a specific set of bundled interventions appears to be a worthwhile strategy, even when there is infectious diseases consultation.
Only two studies have evaluated a bundle approach for the management of candidaemia (Table S4 ). Antworth et al. 56 implemented an active stewardship intervention to improve compliance with bundle elements, including selection of appropriate therapy, removal of intravenous catheters, repeat blood cultures, appropriate duration of therapy and obtaining an ophthalmological examination. Bundle compliance significantly increased with active stewardship intervention compared with no intervention, though no improvements in clinical outcomes were noted. In a large, multicentre study, Takesue et al.
12 evaluated the impact of compliance with a bundle for candidaemia on clinical outcomes. A guideline outlining the bundle of interventions for candidaemia was developed and disseminated in print and on the internet. Additionally, briefing sessions targeted at infection control physicians were performed, though it is unclear whether all front-line treating providers received education. 12 In addition to the elements utilized by Antworth et al., 56 the bundle also incorporated appropriate antifungal dosing, assessment of clinical efficacy on day 3-5 and transition to step-down oral therapy, as appropriate. Survival and clinical success rates were significantly higher among patients with bundle compliance. However, bundle compliance was not independently associated with clinical success or survival after adjusting for patient and fungal factors. Similar to SAB, additional studies are needed to identify the optimal elements to include in a candidaemia bundle, and focusing efforts to achieve key process measures may provide opportunities to improve clinical outcomes.
The majority of studies pertaining to the impact of ASP intervention on BSIs are pre/post studies evaluating ASP active prospective monitoring with feedback and intervention, which has consistently resulted in improvements in processes related to the management of BSIs. Improvements in clinical outcomes, such as LOS and mortality, have been inconsistent and may reflect the complexity of BSIs and difficulties adjusting for potential confounders that may affect outcomes in pre/post studies. Still, pairing interventions with real-time alerting in response to updated blood culture results appears to offer the greatest opportunity to achieve improvements in patient outcomes, even in the absence of RDT. For highrisk BSIs, bundling of evidence-based interventions with active ASP or infectious diseases consultation reinforcement has reliably increased adherence to process measures. However, it remains unclear which interventions or combinations of interventions are most impactful on patient outcomes. Overall, BSIs appear to be a high-yield disease state for active ASP intervention, though studies are warranted to determine how to best utilize hospital resources (e.g. personnel and laboratory equipment) in this complex disease state.
CDI
The number of hospitalized patients with CDI doubled between 2000 and 2009, 57 and CDI is associated with a 2.5-fold increase in mortality 58 and a doubling in hospital costs and LOS. 59 Antibiotic exposure is almost always a prerequisite for CDI, and although nearly all antibiotics have been associated with CDI, clindamycin, cephalosporins (particularly third-generation agents) and fluoroquinolones are associated with conferring the highest risk. 60 Given the impact ASPs can have on antimicrobial use, a significant amount of study has been devoted to their impact on CDI incidence, with a recent systematic review showing that ASPs are associated with a .50% reduction in CDI incidence. 60 While prevention of CDI through drug-based stewardship efforts is essential, there are also opportunities for ASPs to positively impact the care of patients diagnosed with CDI. For example, based on data from retrospective analyses, it is reasonable to hypothesize that prompt initiation of therapy, discontinuation of non-essential concomitant Review antimicrobial and acid-suppressant therapy, and colon-sparing surgery before CDI has irreversibly progressed may improve clinical outcomes. [61] [62] [63] [64] [65] As such, CDI has been targeted for disease-based stewardship initiatives and several institutions have reported on the impact of stewardship intervention on process measures and clinical outcomes (Table S5) . Purely passive interventions, generally consisting of treatment guideline development and education, have produced inconsistent results regarding process measure improvements and have not demonstrated an impact on clinical outcomes. [66] [67] [68] Studies evaluating some type of active intervention have consistently been able to identify improvements in process measures, with treatment concordance significantly improved in all such studies. [69] [70] [71] [72] [73] [74] Other process measures improved with active intervention include time to initiation of therapy, 70,71,74 discontinuation of non-essential acid suppressants 72, 74 and infectious diseases consultation for severe cases. 74 Unfortunately, these improvements in process measures have not translated to a robust impact on clinical outcomes, with only two studies demonstrating such improvements. Jardin et al. 69 implemented an institutional policy granting the ASP the authority to switch patients with severe disease from metronidazole to oral vancomycin. Through these interventions, the use of oral vancomycin for patients with severe CDI significantly increased (14% versus 91%, P , 0.0001). Refractory CDI, defined as diarrhoea continuing after 6 days of CDI therapy, was significantly lowered in the intervention group. However, neither LOS nor in-hospital mortality was significantly improved, and other complications, such as recurrence or ICU admission, were not assessed. In a study by Yeung et al., 71 clinical pharmacists were notified of all positive CDI test results and contacted the medical team in situations where prescribed treatment was discordant with the institutional algorithm. Compared with the preintervention period, treatment concordance was significantly higher in the intervention period (34.0% versus 48.1%, P " 0.01). While mortality, ICU admission and need for colectomy were unchanged between study periods and recurrence was not assessed, the authors demonstrated a decrease in LOS in the intervention group. However, no analysis was performed to independently ascribe this effect to ASP intervention. In contrast, Welch et al., 74 in a study of 592 patients, described the impact of a multifaceted intervention that included ASP pharmacists receiving real-time alerts for positive CDI results and recommending guideline-concordant therapy, discontinuation/de-escalation of non-essential antimicrobials and acid suppressants, and infectious diseases and/or surgical consultation when appropriate. Despite significant improvements in several process measures, attributable mortality, ICU admission, need for colectomy/ileostomy and CDI recurrence were not significantly impacted.
In conclusion, although CDI would appear to be an ideal target for disease-based stewardship initiatives, studies evaluating such interventions have not been able to identify consistent, significant improvements in clinical outcomes, despite improvements in process measures. At this time, institutions should weigh whether ASP resources devoted to disease-based stewardship of CDI would be best directed elsewhere. Given the low baseline rates of complications attributable to CDI noted in the available studies (such as by Welch et al. 74 ), further research is needed to assess whether ASP intervention may improve outcomes in institutions with higher rates of such complications.
ASB and UTIs
One of the most explored areas for disease-based stewardship practice is for UTIs and ASB. ASP-directed intervention for UTI and ASB presents as an area of opportunity due to the high volume of targetable patients and the ecological and collateral damage associated with antimicrobials commonly prescribed for UTI and ASB, chiefly fluoroquinolones. 75, 76 Treating ASB can lead to the subsequent emergence of antimicrobial resistance and drugrelated adverse effects, yet has not been associated with improved clinical outcomes for the majority of the population. [77] [78] [79] Nonetheless, overtreatment of ASB occurs in 50% of patients 78, 80, 81 and thus presents a continuing challenge at many institutions.
Many multifaceted ASP interventions have been implemented with varying, yet overall positive, results for UTI and ASB management (Tables S6 and S7 ). Passive stewardship strategies, such as education and guideline development, have been commonly used to reduce antimicrobial use for ASB, with a focused effort on improving differentiation between ASB and true UTI. Numerous studies of passive interventions have shown successful results by reducing antimicrobial treatment of ASB. [82] [83] [84] [85] [86] [87] [88] [89] [90] A unique intervention was evaluated by Leis et al., 91 where reporting of positive urine cultures was suppressed in the electronic medical record for noncatheterized patients; clinicians were required to call the microbiology laboratory to obtain results if there was a high suspicion of true infection. With this passive intervention alone, the rate of ASB treatment was significantly reduced (48% versus 12%, P " 0.002), with no episodes of sepsis or cases of untreated UTI identified during the study period. While many passive strategies employ education, the type and intensity of these efforts vary greatly. McMaughan et al. 89 sought to assess whether differences in education (low-versus high-intensity training), when combined with the implementation of a decision-making aid, impacted rates of ASB treatment at 12 nursing homes. The high-intensity group received two training sessions during the intervention period, with active technical support, in contrast to the low-intensity group, which received one educational session, with technical support available upon request. Neither group saw significant reductions in prescriptions written for ASB. Further exploration into how to optimize educational tactics is necessary.
There is a paucity of literature describing active stewardship interventions in patients with ASB. Kelley et al. 92 utilized a multifaceted approach involving presentations to physicians and clinical pharmacists, development of resource materials, as well as active daily ASP review of common antimicrobials prescribed for UTIs. Through these measures, unnecessary empirical antimicrobial therapy was reduced from 62% to 26% (P , 0.0001). Leis et al. 93 also utilized prospective audit and feedback, focusing on noncatheterized patients with positive urine cultures. The ASP reviewed patient profiles with positive urine cultures for signs and symptoms of infection and wrote recommendations in the medical record to discourage antimicrobial treatment for ASB. This resulted in reduced duration of antibiotic therapy in the intervention group, but no change in initial treatment of ASB. Navigating away from traditional daily ASP review, Doernberg et al. 86 designed and implemented an approach utilizing active ASP evaluation at three long-term care facilities (LTCFs). Once a week, the ASP conducted audit and feedback of prescriptions for UTIs, which resulted in a Review JAC modest reduction in prescription rates. However, 85% of the prescriptions not reviewed by the ASP were unnecessary, suggesting more frequent audit and feedback may be more fruitful, albeit potentially unfeasible in resource-limited settings such as LTCFs. Although there are limited studies on active methods, current published evidence suggests similar outcomes when active or passive methods are utilized, raising the question of whether resourceheavy active initiatives are necessary in the area of ASB.
There are few studies evaluating the impact of disease-based stewardship initiatives for the management of UTIs. Given the broad spectrum of activity, associated CDI risk and concern for adverse drug events, the use of fluoroquinolones for uncomplicated UTIs is discouraged by major guidelines. 75, 81 Despite this, fluoroquinolones are still frequently used for the treatment of uncomplicated UTIs given their ease of dosing and high oral bioavailability. Thus it is not surprising that ASP interventions have largely focused on antibiotic selection for UTIs.
Through education and guideline implementation, ASPs have increased nitrofurantoin and fosfomycin use for cystitis, antimicrobials associated with a lower propensity for collateral damage.
94-96 Duration of therapy [97] [98] [99] [100] and guideline compliance 95, 97 have also improved with the use of passive antimicrobial stewardship interventions. For example, the implementation of an electronic order set based on institutional guidelines for use in an emergency department increased guideline compliance (44% versus 68%, P , 0.001), reduced fluoroquinolone use for cystitis (44.4% versus 14.5%, P , 0.001) and reduced the duration of therapy for cystitis (5.6 versus 3.9 days, P , 0.001). 97 Additionally, a study in 24 nursing homes demonstrated that educational sessions and one-on-one meetings with physicians reduced antimicrobial use, without negative impacts on rates of hospital admission or mortality. 98 Education on local uropathogen resistance rates through use of posters and periodic e-mails dramatically improved prescription patterns for UTIs at three emergency centres. 96 Notably, although use of nitrofurantoin significantly increased, two patients with pyelonephritis were also inappropriately prescribed this agent, suggesting that educational efforts need to be carefully designed.
As illustrated, the majority of stewardship literature for ASB and UTI support the use of passive interventions. Although there are few studies evaluating the use of active interventions for UTI and ASB, the outcomes achieved with the active interventions explored to date are not substantially greater than those achieved with passive interventions, which require fewer resources and dedicated ASP personnel to maintain. The promising results with education and guideline development alone suggest that passive, disease-based strategies can have substantial impacts on ASB and UTI management in a variety of practice settings, including emergency centres and nursing homes. However, studies assessing the effects of these initiatives on outcomes such as rates of CDI and antimicrobial resistance are lacking.
IAIs
IAIs are common and complicated IAIs are associated with significant morbidity and mortality. 101 The IDSA and Surgical Infection Society guidelines for the management of IAIs stratify therapy based on disease severity and risk factors for colonization with MDR pathogens. 101, 102 Emerging publications demonstrate shorter courses of therapy are appropriate for complicated IAIs, especially following timely surgical intervention and source control. 101, 103, 104 Despite these studies and guideline recommendations, broadspectrum antibiotic overuse and excessive duration of antibiotic therapy persist. [105] [106] [107] Thus, ASPs have several potential targets to improve the management of IAIs, including limiting unnecessary broadspectrum antimicrobial therapy, prompting appropriate transition from intravenous to oral therapy, optimizing duration of therapy and providing recommendations to avoid specific antibiotics in the setting of high resistance rates. Four studies have evaluated clinical outcomes following implementation of ASP initiatives targeting patients with IAIs [105] [106] [107] [108] (Table S8 ). All four studies utilized solely passive stewardship techniques through education and implementation of guidelines to impact therapy and outcomes.
Popovoski et al. 105 implemented an institutional guideline with the objective of limiting anti-pseudomonal therapy for community-acquired uncomplicated infection by promoting ceftriaxone and metronidazole and recommending piperacillin/tazobactam only for hospital-acquired or life-threatening infection. They reported reductions in days of therapy for ciprofloxacin and piperacillin/tazobactam, while increasing ceftriaxone use. These positive impacts on antimicrobial use did not lead to negative impacts on clinical outcomes, as mortality and hospital readmission were similar between groups. Likewise, Dubrovskaya et al. 107 implemented a guideline aimed at minimizing ciprofloxacin and ampicillin/sulbactam utilization due to increasing antibiotic resistance based on their institutional antibiogram. Passive guideline implementation achieved reductions in the use of those antimicrobial agents while increasing the utilization of cefoxitin. Of note, the post-guideline group was associated with a numeric increase in patients receiving appropriate antibiotic coverage when intraabdominal cultures were positive. Mortality and length of hospitalization were similar between groups and a non-significant reduction in hospital-acquired CDI was noted. Skarda et al. 106 implemented a guideline focused on optimizing days of therapy based on clinical response and facilitating appropriate oral stepdown therapy in paediatric patients with appendicitis. Following guideline implementation, the number of post-operative antibiotic doses decreased and more patients transitioned to oral therapy to avoid peripherally inserted central catheter placement. This guideline led to reductions in LOS and total hospital cost. No differences in hospital readmission, presentation to emergency department following discharge, need for re-operation or interventional radiology drainage were noted. Finally, Cai et al. 108 developed a procalcitonin-based guideline for use in patients with acute pancreatitis. They evaluated guideline compliance and noted a significant reduction in days of antibiotic therapy (3.3 versus 6.3 days, P , 0.0010), without adversely affecting clinical outcomes, including mortality, ICU stay, surgical intervention and resolution of fever and leucocytosis.
In summary, passive stewardship strategies aimed at improving the management of IAI have been successful in optimizing antimicrobial use, without compromising patient outcomes. Evaluation of active and combination disease-based measures would be of great interest to see whether these positive results could be further enhanced.
Review

Pneumonia
In the USA, pneumonia is the leading infectious cause of hospitalization, 109 is associated with high readmission rates 110 and represents a significant financial burden on the healthcare system. 111 Quality performance measures relating to the management of patients with pneumonia have been incorporated into The Joint Commission accreditation standards and Medicare's Hospital Value-Based Purchasing Program, which provide incentivized payments based on the quality of care achieved. 4 Adherence to national treatment guidelines can reduce mortality and LOS in hospitalized patients with community-acquired pneumonia (CAP). [112] [113] [114] Thus, there are several opportunities for ASPs to optimize the treatment of pneumonia (Tables S9 and S10 ). The most common strategy has been implementation of a clinical pathway or institutional guideline providing direction on diagnosis and/or treatment including optimal antibiotic agent, dose and duration. Implementation of passive guidance has consistently improved rates of appropriate antibiotic therapy [115] [116] [117] [118] [119] [120] [121] [122] [123] and has shifted antibiotic utilization from broad-spectrum to narrowerspectrum agents. 122, 124, 125 Furthermore, although few in number, larger studies suggest an improvement in clinical outcomes, including mortality, hospitalizations and LOS, may be achieved following the implementation of a CAP guideline. 117, 118, 120 For example, in a multicentre randomized trial, implementation of a decision pathway consisting of admission criteria, practice guidelines and medication therapy led to favourable antibiotic-related outcomes as well as improved clinical outcomes, including a reduction in LOS (5 versus 6.7 days, P " 0.01) and admission of lowrisk patients (31% versus 49%, P " 0.01) for patients with CAP. 120 Although significant improvements in clinical outcomes are not consistently seen using this passive strategy, importantly, several studies demonstrate that a change in antibiotic use does not adversely impact clinical outcomes in patients with CAP. 117, 118, [120] [121] [122] 124, 125 Thus, implementation of a comprehensive guideline for the treatment of pneumonia is a safe and effective way to improve antibiotic use.
Misdiagnosis of bacterial pneumonia can lead to overuse of antibiotics. Therefore, several studies have evaluated the utility of incorporating procalcitonin, a biomarker for bacterial infection, into treatment guidelines for respiratory tract infections as a method to reduce antibiotic initiation and overall use. [126] [127] [128] [129] A metaanalysis of 14 trials demonstrated a significant reduction in antibiotic duration (10 versus 7 days, P , 0.0001) without compromise in clinical outcomes when a procalcitonin algorithm was used in patients with CAP. 129 However, these clinical trials were conducted in primarily non-critically ill patients. Interestingly, a recent study conducted in real-world settings of critically ill patients demonstrated increased antibiotic exposure when a procalcitonin algorithm was utilized. 130 While procalcitonin has the potential to reduce antibiotic use and can be implemented into algorithms, more data are needed to evaluate its impact on outcomes in a variety of patients and settings. Moreover, studies incorporating active, real-time intervention by ASPs to interpret and provide treatment recommendations based on biomarker results are warranted.
Studies of active interventions including implementation of treatment pathways with audit and feedback have shown significant improvements in both antibiotic (selection, initiation, duration) and clinical outcome (namely hospital LOS) measures. [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] Wilde et al. 131 demonstrated positive results when combining a computerized clinical pathway with prospective audit and feedback by an ASP in a study of ventilator-associated pneumonia (VAP) patients. Patients who were treated according to the pathway were more likely to receive appropriate antibiotics within 24 h (82.1% versus 36.1%, P , 0.001) and time to appropriate antibiotics was significantly decreased. 131 When use of the pathway became voluntary and real-time prospective audit with active intervention by the ASP was removed from this initiative, compliance with the pathway decreased from 100% to 44%. Additionally, a randomized controlled trial conducted in patients with CAP showed that intravenous-to-oral conversion resulted in a reduction in mean LOS (9.6 versus 11.5 days) without negatively impacting clinical cure rates and mortality. 133 Avdic et al. 132 aimed to optimize duration of therapy through enforcement of IDSA criteria for antimicrobial discontinuation in CAP. This active intervention resulted in significant decreases in duration of therapy (7 versus 10 days, P , 0.001), with numerical decreases in 30 day readmission (7.7% versus 14.5%, P " 0.22) and CDI (1.5% versus 4.8%, P " 0.28) rates. Finally, reduction in MRSA-targeted therapy and subsequently rates of acute kidney injury were observed in a study by Baby et al. 141 evaluating the impact of a pharmacist-driven active surveillance protocol using negative nasal MRSA PCR testing to make changes to empirical antibiotic therapy.
Overall, implementation of treatment guidelines and comprehensive clinical pathways for pneumonia, with or without active intervention, can reduce unnecessary broad-spectrum antibiotic use and influence clinical outcomes. A potential strategy might include development of a comprehensive clinical pathway that incorporates admission criteria, use of biomarkers, criteria for intravenous to oral therapy conversion, and empirical antibiotic and duration of therapy recommendations. The addition of active stewardship intervention to ensure pathway compliance also appears to improve clinical outcomes, particularly reducing length of hospitalization, although daily audit and intervention may be challenging given the volume of patients that present with pneumonia at most institutions. Although most of the published data are for CAP, similar strategies may be applied to patients with other pneumonias as well. Future studies should focus on the role of a comprehensive ASP approach in understudied types of pneumonia, including VAP and hospitalacquired pneumonia.
ABSSSIs
The incidence of ABSSSIs is increasing, with reports of up to a 29% increase in attributable hospital admissions described over a 4 year period, 142 a striking trend also evident in the outpatient setting. 143, 144 Patients with ABSSSIs have increased lengths of hospitalization when compared with uninfected hospitalized patients, leading to excess healthcare expenditures with frequent use of potentially unnecessary diagnostic studies, broad-spectrum antibiotic therapy and often unnecessarily long treatment courses. 145, 146 Furthermore, the empirical use of MRSA-active antibiotics for uncomplicated cellulitis has increased dramatically despite data suggesting that MRSA is an uncommon pathogen. 147, 148 Review JAC The role of ASPs and potential impact of intervention in patients with an ABSSSI has not been widely studied (Table S11) . Three studies evaluated clinical and drug utilization outcomes following intervention on antibiotic therapy by an ASP. 149, 150 All studies utilized active stewardship techniques, providing real-time feedback with intervention. The impact of a multifaceted intervention including the development of a clinical practice guideline, use of a computerized order set for cellulitis and abscesses, provider education and audit with feedback was evaluated in a study by Jenkins et al. 151 Duration of therapy (13 versus 10 days, P , 0.001) and exposure to broad-spectrum Gram-negative antibiotics (66% versus 36%, P , 0.0001) were successfully reduced in the intervention group. 151 In a study by Pasquale et al., 149 the ASP pharmacist actively identified patients with ABSSSIs and made several recommendations, including recommendations to change antibiotic regimen and dosing and to obtain infectious diseases consultation, with an overall acceptance rate of 95%. When compared with historical data, these interventions resulted in decreases in LOS (4.4 versus 6.2 days, P , 0.001) and readmission (6.5% versus 16.7%, P " 0.05). Similarly, Loo et al. 150 demonstrated that active ASP intervention led to significant decreases in LOS (7 versus 12 days, P , 0.01) and duration of therapy (6 versus 8 days, P , 0.01) without adversely impacting attributable mortality. These studies suggest active ASP intervention not only results in improved antibiotic use, including duration of therapy, but also can reduce hospital LOS, which has previously been identified as excessive.
RDT can aid in the identification of resistant organisms and subsequently impact targeted antibiotic therapy. Terp et al. 152 evaluated clinical outcomes in patients with ABSSSIs following implementation of a protocol utilizing a rapid MRSA PCR assay on wound culture swabs for patients with purulent infections. A separate phase of this intervention involved active review of test results by pharmacists, who made antibiotic treatment recommendations in the emergency department. In this study, no significant difference in the duration of therapy or the proportion of patients receiving antibiotics that were discordant with the PCR results was identified. However, the assay was not consistently used, and if PCR results were always used to guide antibiotic therapy, rates of discordant antibiotic use were estimated to significantly decrease from 58% to 6.5%. In a study by Yu et al., 153 use of a PBP2a antigen test for wound, abscess and skin cultures was evaluated. Results were entered into patient charts and sent to the ASP by the microbiology laboratory. An ASP pharmacist reviewed these results and made recommendations for antibiotic therapy. Following the implementation of this initiative, significant improvements in targeted antibiotic therapy (74% versus 88%, P " 0.008) and median LOS (60 versus 47 h, P " 0.018) were observed. 153 Improving outpatient management of ABSSSI is important as the number of patients presenting to ambulatory clinics with this disease is rising. 143, 144 Two large studies evaluated the use of passive interventions including treatment and diagnostic algorithms with concurrent provider and patient education to improve empirical antibiotic therapy. Interestingly, both resulted in an increase in use of MRSA-targeted antibiotic therapy. 154, 155 However, the studies do not evaluate whether or not use of MRSA-targeted antibiotic therapy was appropriate or inappropriate. Further studies in the outpatient setting, including those evaluating clinical outcomes, are warranted.
In summary, the existing literature evaluating the impact of disease-based stewardship for ABSSSIs suggest that active strategies involving review of and intervention in antimicrobial therapy by an ASP can significantly improve appropriate antibiotic use, decrease duration of therapy and reduce LOS. RDT coupled with realtime ASP intervention has not demonstrated consistent benefits and requires further evaluation. Additionally, few studies have evaluated the use of passive interventions and have only been performed in the outpatient setting. Generally, more studies evaluating the role of ASPs in the management of patients presenting with ABSSSIs, particularly in outpatient settings, are needed.
Discussion and conclusions
It is well established that ASPs can improve antimicrobial use and reduce drug expenditures. Recognition of these successes has allowed ASPs to garner additional resources that enable their expansion to initiatives that target clinical outcomes and support institutional efforts focused on quality and safety. By targeting specific infectious diseases, ASPs can identify high-risk patient populations and make interventions with measurable and tangible gains. This review suggests disease-based stewardship results in improved process measures and antimicrobial-related outcomes through both passive and active interventions. Yet improvements in clinical outcomes have not been consistently observed. The variable effects on clinical outcomes suggest two findings: (i) the clinical impact of disease-based stewardship varies based on disease state; and (ii) the optimal intervention, or combination of interventions, resulting in the most positive impact on outcomes has not been identified for most disease states.
Many pre/post studies evaluating active interventions for the management of BSIs have observed improvements in clinical outcomes, including mortality, LOS and clinical success. This is in contrast to CDI, where even robust active interventions resulted in limited impact on clinical outcomes. Similarly, limited impacts on patient outcomes were seen with ASB and UTI interventions, regardless of passive or active intervention. These results perhaps should not be unexpected; BSIs are associated with high attributable morbidity and mortality, and thus there may be significant opportunity for ASP influence on outcomes. In contrast, infections such as UTI and CDI are associated with fewer adverse outcomes, making it less likely for ASP intervention to have a significant impact on these measures. Nonetheless, interventions for these less severe infectious states demonstrated significant improvements in antimicrobial-related outcomes across all infection types, without any concomitant increase in adverse clinical outcomes, and their impact should not be understated or underappreciated.
One of the most important considerations when designing and implementing stewardship initiatives is an assessment and allocation of resources to optimize efficiency and effectiveness. Most ASP programmes have a limited capacity to perform daily prospective audit and feedback for all infections, and must prioritize efforts to those that have the highest yield. In addition to dedicated ASP personnel, such as infectious diseases physicians and pharmacists, resources and support from the microbiology or molecular laboratory and information technology are crucial. This is especially important to consider when incorporating the use of RDT methodologies, as interdisciplinary collaboration is fundamental when determining the highest-yield instrument to select and Review when creating a workflow of procedures for real-time alerting and intervention. RDT is a large financial investment and consideration should be given to costs associated with implementation. However, cost analyses evaluating the financial impact of implementing RDT with ASP intervention suggest a potential for overall reduced hospital costs for BSIs due to improvements in clinical outcomes. 20, 21, 30, 156 Still, if resources to perform active intervention or purchase RDT are limited, passive methods such as guideline development and education alone may be considered and have been successful for a variety of disease states.
There are notable strengths and weaknesses for active and passive intervention methodologies. Although upfront implementation may require substantial time and effort, passive interventions require less regular, dedicated ASP resources and personnel. Consequently, passive strategies are appealing to a variety of resource-limited practice settings, including nursing homes, LTCFs and community hospitals. Still, the long-term effects of passive strategies are not well understood. Educational interventions and guideline implementation, two of the most common passive approaches, have measurable short-term impacts, yet the longterm durability of these initiatives is unknown, creating concern that effects may diminish over time. This may be of concern especially in settings with a high provider turnover rate, such as academic medical centres with new trainees annually. Active initiatives, such as prospective monitoring of blood cultures, require dedicated resources and personnel to regularly identify patients and perform interventions. These methods may be challenging at larger institutions with a high volume of infections and complex patient populations, where considerably more resources and expertise are needed to maximize efficiency and optimize outcomes. While the benefits of active initiatives may not wane over time, the consistent consumption of ASP resources may impede the development and implementation of new initiatives. Notably, repeated feedback given directly to providers may have long-term effects on individual prescribing practices, though this has yet to be quantified in studies. Selection of active or passive approaches should be based on the targeted disease state and tailored to meet institutional goals according to available resources.
Though the volume of published literature in disease-based stewardship has increased, there are still many unanswered questions. Almost all literature on disease-based stewardship intervention is retrospective or pre/post in nature. Though the limitations inherent to these types of studies can be mitigated by logistic regression or propensity-score matching, randomized controlled trials are crucial for evaluating the impact of specific interventions on outcomes and may result in conclusions differing from those observed in retrospective studies, as was the case with the BSI studies. Furthermore, there is a lack of direct comparison between active and passive stewardship methods to elucidate which approach is more impactful. Finally, there are many undetermined factors within the scope of passive or active approaches. For example, although passive methods can reduce inappropriate antimicrobial treatment of ASB, the type of passive method (i.e. guideline versus education versus algorithms) is not yet well delineated and likely depends on barriers specific to the institution. Future studies should attempt to address these important gaps in evidence.
Even so, certain key conclusions can be made based on available literature for the infectious disease states discussed in this review. For BSIs, active interventions improve antimicrobial-related process measures, but improvements in clinical outcomes are inconsistent and have not been observed in published randomized controlled trials. For CDI, active interventions are associated with significant improvements in process measures, but have not demonstrated meaningful improvements in clinical outcomes. Regarding UTI and ASB, passive and active strategies have reduced inappropriate duration of antibiotic therapy and reduced inappropriate or suboptimal antibiotics, without increasing adverse clinical outcomes. No active stewardship studies have been conducted for IAI; nevertheless, passive interventions have improved antimicrobial-related outcomes. For pneumonia, implementation of clinical pathways and treatment guidelines, with or without active intervention, may decrease unnecessary broad-spectrum antibiotic use and influence clinical outcomes. Lastly, active interventions varied greatly for ABSSSIs with inconsistent effects, yet still signal towards potential ability to reduce LOS.
Many ASP programmes are expanding upon the traditional stewardship focus on antimicrobial utilization and cost to now incorporate dedicated efforts in disease-based stewardship. This trend will likely continue given literature suggesting potential improvements in outcomes, and endorsement by the 2016 IDSA/ SHEA stewardship implementation guidelines. Review of published studies highlights the major gaps that exist in regard to optimizing disease-based stewardship initiatives. Much remains to be elucidated in the practice of disease-based antimicrobial stewardship. As studies continue to be conducted, the optimal strategies to utilize for specific infectious diseases will become better defined and this will help ASP programmes best allocate resources and focus interventions in order to optimize patient outcomes.
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